生物技术公司Kymera Therapeutics, Inc.今日宣布，其合作伙伴吉利德科学已正式行使选择权，获得口服Cdk2分子胶降解剂开发候选药物KT-200的授权许可。这一决定标志着双方在创新肿瘤疗法合作中的重要里程碑。
KT-200作为一款具有突破潜力的口服分子胶降解剂，专注于靶向细胞周期蛋白依赖性激酶2（Cdk2），该靶点在与多种癌症相关的细胞周期调控中扮演关键角色。通过分子胶降解技术，KT-200旨在高效降解致病蛋白，为肿瘤治疗提供新机制。
此次选择权的行使，不仅验证了Kymera Therapeutics在蛋白质降解领域的研发实力，也为吉利德科学扩充其肿瘤管线增添了重要资产。双方将继续推进该候选药物的后续开发工作，加速其向临床应用的转化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.